Almost 60% of patients do not have enough knowledge about biosimilar medicines

by time news

Updated:03/06/2022 13: 46h

Save

The ProPatiens Institute has carried out a study, with the collaboration of the Patient Chair, to “determine the perception of patient associations and their members about the degree of knowledge, familiarity, training and information” regarding the biosimilar medicines. One of the most relevant conclusions is that the vast majority of respondents, 56.9%, do not have sufficient knowledge of them. In fact, only 36.3% of those who know them state that they have an acceptable degree of knowledge (score of 4 and 5 out of 5).

Another relevant aspect of the study is related to the information sources What do they use. In this sense, who provides them with more information about biosimilar drugs is the doctor (40.9% of cases) and 27.3%, that is, one in four, obtains it from the Internet.

The rest is distributed in a minority among nursing staff, pharmacists, patient associations and other agents involved in the process.

An interesting aspect is that the majority of those surveyed, 97.1%, request and would especially appreciate having access to informative and training sessions aimed at patients about this type of treatment, given through independent, recognized and prestigious organisations. .

102 national and regional patient associations have participated in the study. Those in charge of answering the survey have been fundamentally women (85.3%) residing in the Autonomous Community of Madrid (26.5%), Andalusia (13.7%), Castilla y León and Galicia with 11.8% of those surveyed, respectively, the Valencian Community (8.8%), Catalonia with 7.8%, the Basque Country (4.9%) and the rest of the territories in lower percentages.

A methodology has been designed that includes a quantitative, observational, descriptive and cross-sectional field study, where the participants have been asked about nine simple, clear and easily understood questions related to the personal and educational sociodemographic profile, and fundamental aspects about biosimilar medicines. All this, through an online questionnaire that aimed directly at obtaining a specific response regarding the main objective of this analysis, which allows establishing specific strategies and specific action plans for the present and future.

See them
comments

You may also like

Leave a Comment